Intraoperative Liposomal Bupivacaine Is Associated With Reduced Opioid Use and Enhanced Recovery After Total Knee Arthroplasty: A Multicenter Registry Study

Authors

• Mitchell Ng, Thomas Jefferson UniversityFollow
• Jennifer Lin
• Andrew Spitzer
• Vinod Dasa
• Adam Rivadeneyra
• David Rogenmoser
• Andrew Concoff
• Mary DiGiorgi
• Joshua Urban
• William Mihalko
• Michael Mont

Document Type

Article

Publication Date

4-29-2026

Comments

This article is the author’s final published version in Arthroplasty Today, Volume 39, 2026, Article number 101968.

The published version is available at https://doi.org/10.1016/j.artd.2026.101968. Copyright © 2026 The Authors.

Abstract

BACKGROUND: With an annual volume of total knee arthroplasties (TKAs) in the United States projected to exceed 1.5 million by 2050, optimizing perioperative pain control and facilitating early discharge remain clinical priorities. This study evaluated the effectiveness of liposomal bupivacaine (LB) vs conventional bupivacaine/ropivacaine in opioid-naïve patients undergoing primary TKA, comparing/contrasting: (1) pain score improvements, (2) opioid usages, (3) functional recoveries, and (4) hospital lengths of stay.

METHODS:  Data from the Innovations in Genicular Outcomes Research (iGOR) registry were used to identify patients undergoing unilateral primary TKA between September 2021 and December 2024. Two hundred twenty-five patients were analyzed, 42 receiving LB and 183 receiving conventional local anesthetics. Patients were stratified based on intraoperative analgesia; pain was assessed using the Brief Pain Inventory-Short Form; opioid use was self-reported; function was measured with the Knee Injury and Osteoarthritis Outcome Score for Joint Replacement. Comparative analyses were performed using generalized linear mixed-effects regressions, with significance P < .05.

RESULTS: The LB group showed lower average Brief Pain Inventory-Short Form scores in the early postoperative period (2.6 vs 2.9; P = .03), reduced opioid use at 3 months (24 vs 41%; P < .001), and improved Knee Injury and Osteoarthritis Outcome Score for Joint Replacement scores (65.2 vs 63.9; P = .004). Patients receiving LB were discharged 5.6 hours earlier than controls (15.0 vs 20.6 hours; P = .007).

CONCLUSIONS: Use of LB is associated with improved pain control, reduced opioid use, and shorter lengths of stay following TKA. This study highlights LB's utility in facilitating early mobilization and advancing perioperative care.

Recommended Citation

Ng, Mitchell; Lin, Jennifer; Spitzer, Andrew; Dasa, Vinod; Rivadeneyra, Adam; Rogenmoser, David; Concoff, Andrew; DiGiorgi, Mary; Urban, Joshua; Mihalko, William; and Mont, Michael, "Intraoperative Liposomal Bupivacaine Is Associated With Reduced Opioid Use and Enhanced Recovery After Total Knee Arthroplasty: A Multicenter Registry Study" (2026). Rothman Institute Papers. Paper 326.
https://jdc.jefferson.edu/rothman_institute/326

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Language

English